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Abstract
McArdle disease is caused by lack of glycogen phosphorylase (GP) activity in skeletal muscle. Patients experience exercise
intolerance, presenting as early fatigue and contractures. In this study, we investigated the effects produced by a lack of GP
on several genes and proteins of skeletal muscle in McArdle patients. Muscle tissue of 35 patients and 7 healthy controls
were used to identify abnormalities in the patients’ transcriptomic profile using low-density arrays. Gene expression was
analyzed for the influence of variables such as sex and clinical severity. Differences in protein expression were studied by
immunoblotting and 2D electrophoresis analysis, and protein complexes were examined by two-dimensional, blue native
gel electrophoresis (BN-PAGE). A number of genes including those encoding acetyl-coA carboxylase beta, m-cadherin,
calpain III, creatine kinase, glycogen synthase (GS), and sarcoplasmic reticulum calcium ATPase 1 (SERCA1), were found to be
downregulated in patients. Specifically, compared to controls, GS and SERCA1 proteins were reduced by 50% and 75%
respectively; also, unphosphorylated GS and SERCA1 were highly downregulated. On BN-PAGE analysis, GP was present
with GS in two muscle protein complexes. Our findings revealed some issues that could be important in understanding the
physiological consequences of McArdle disease: (i) SERCA1 downregulation in patients could result in impaired calcium
transport in type II (fast-twitch) muscle fibers, leading to early fatigability during exercise tasks involving type II fibers (which
mostly use glycolytic metabolism), i.e. isometric exercise, lifting weights or intense dynamic exercise (stair climbing,
bicycling, walking at a very brisk pace), (ii) GP and GS were found together in two protein complexes, which suggests a new
regulatory mechanism in the activity of these glycogen enzymes.
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Introduction
McArdle disease (glycogen storage disease type V) is an
autosomal recessive disorder caused by a deficiency of muscle
glycogen phosphorylase (GP), the enzyme that catalyzes the first
step in glycogen catabolism [1,2]. Because of this deficiency, daily
life activities involving isometric exercise (e.g. lifting weights) or
dynamic exercise (e.g. stair climbing) trigger exercise intolerance in
McArdle patients, which manifests as early fatigue and contrac-
tures, sometimes accompanied by rhabdomyolysis and myoglo-
binuria [3]. Any muscle in the body can be affected and
approximately one-third of the patients also develop proximal
muscle fixed weakness and wasting with aging [4,5].
The rationale for exercise intolerance in these patients has been
traditionally explained through metabolic depletion. Blockade of
glycogen breakdown compromises aerobic and anaerobic glycol-
ysis [6]. The oxidative capacity of the patient’s muscle is also
impaired because of their ability to produce pyruvate - a molecule
that plays an anaplerotic role in the Krebs cycle - is severely
reduced [3]. Nonetheless, it is also of note that the extent of the
oxidative defect is substrate dependent; i.e., it can be partially
corrected by increasing the availability of alternative oxidative
substrates (e.g. glucose) to working muscles [7]. The reduced
potential for oxidative phosphorylation is reflected by marked
reduction in the [ATP]/[ADP][Pi] ratio during muscle contrac-
tions compared with healthy controls (as shown with phosphorus
magnetic resonance spectroscopy) [8]. With regard to this, the
premature muscle fatigue and cramping of McArdle patients is
associated with an increased accumulation of Pi and probably
ADP in skeletal muscle; accumulations of Pi and ADP are indeed
known to inhibit (i) myofibrillar, (ii) sarcoplasmic reticulum (SR)
Ca
2+, and (iii) membrane Na
+-K
+-ATPase reactions
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which is not necessarily related to exercise intolerance is the
chronically high subsarcolemmal and intermyofibrillar glycogen
store deposits that are present in patients’ muscles [9,10].
Glycogen synthesis is catalyzed by the enzyme, glycogen
synthase (GS), which exerts the opposite function of GP. Both
enzymes share regulatory mechanisms: covalent modification,
allosteric activation, and enzymatic translocation [11]. The role
of GS in glycogen accumulation is not fully understood, and a
decrease in GS activity has been reported in McArdle patients
[10,12]. The activity of enzymes regulating covalent modifica-
tion of GS, glycogen synthase kinase and protein phosphatase 1,
do not explain the reduction in GS activity present in the
patients [12].
In this study, we characterized the transcriptomic profile of a
selection of key genes involved in the maintenance of skeletal
muscle function. We identified other chronic protein alterations
that occur in the muscle of McArdle patients in addition to GP
deficiency: (i) a near absence of the unphosphorylated SERCA1;
and (ii) a reduction of GS, with a shift through the inactive forms
of both proteins. Furthermore, protein studies suggested that GP
binds with GS to form protein complexes, thereby creating an
additional mechanism to regulate glycogen metabolism.
Materials and Methods
Subjects
35 Spanish McArdle patients (P1–P35), some of them previously
characterized by molecular techniques [13,14,15,16] were includ-
ed in the study (Table 1). To avoid differences due to lower muscle
training compared with non-patients, 7 healthy volunteers with
sedentary life-style habits were used as controls (C1–C7). Age
range was 17 to 71 years in the patient group and 23 to 50 years in
the control group. Patients presented a broad representation of the
different clinical severity groups, in accordance with a previously
reported scale by Martinuzzi et al. [17]. Patients P1–P34 and
controls C1–C5 were studied in the RNA analysis. Later, patient
P35, and controls C6 and C7 were included in the studies of 2D
and blue native gel electrophoresis, due to the high amount of
protein needed for these analyses. Written consent was obtained
from all participants. The study was approved by the Ethics
Committee of Hospital Universitario 12 de Octubre and was performed
in accordance with the Declaration of Helsinki for Human
Research. A skeletal muscle biopsy was obtained from patients and
controls.
Low Density Array (LDA) and Real-Time PCR analysis
RNA samples were obtained as previously described [13].
Customized low-density arrays (LDAs) were configured to study 48
genes (see Supplementary Table S1) using TaqMan assays
(Applied Biosystems, Foster City, CA, USA). The genes we
studied play an important role in major muscle functions:
metabolism, membrane transport, mitochondrial function/bio-
genesis and dynamics, maintenance of cytoskeleton, contractile
function, calcium reuptake in sarcoplasmic reticulum, control of
muscle growth, atrophy and differentiation, neuromucular trans-
mission, anti-stress protection, inflammation and cell death.
Samples were run in duplicate on the ABI 7900HT system
(Applied Biosystems). The PCR conditions were 2 min at 50uC
and 10 min at 94.5uC, followed by 50 cycles of two steps, 30-s at
97uC and 1 min at 59.7uC. Cyclophilin A (PPIA) was used for
data normalization, the calibrator sample was C2, and the
software for the analysis was SDS 2.3 and RQ 1.2 (Applied
biosystems). The muscle GP (PYGM) (Hs00194493_m1) and
leptin (LEP) (Hs00174877_m1) genes were quantified by real-time
PCR using TaqMan fluorogenic probes, as described elsewhere
[13].
Immunoblot Analysis
Skeletal muscle specimens were homogenized in 40 mM b-
glycerophosphate, 40 mM NaF, 10 mM EDTA, and 20 mM
mercaptoethanol (pH 6.8). Proteins were resolved on 10% SDS
polyacrylamide gel. Antibodies against SERCA1, calpain 3,
muscle cadherin (m-cadherin) (Abcam, Cambrige, UK), muscle
GS (Cell signaling, Danvers, USA), and muscle GP (primary
antibody generated in Dr. Martinuzzi’s laboratory) were utilized.
The horseradish peroxidase-conjugated secondary antibodies
included goat anti-mouse, goat anti-rabbit (Jackson Laboratories,
PA, USA), and donkey anti-goat (Santa Cruz, Santa Cruz, CA,
USA). Membranes were developed with ECL (Amersham,
Buckinghamshire, UK). Images were obtained with a LAS-3000
system (FujiFilm, Tokyo, Japan) and quantified with NIH image J
(version 1.37) software (Scion image, NIH). Cyclophilin A (Enzo
Life Sciences, Plymouth Meeting, PA, USA) was used as the
housekeeping protein.
2D electrophoresis Analysis
Skeletal muscle was homogenized in lysis buffer (10 mM Tris
pH 8.0, 1 mM EDTA, 150 mM NaCl, 10 mg/mL leupeptin,
10 mg/mL aprotinin, 10 mg/mL pepstatin A, and 0.5 mM PMSF).
Seventy micrograms of protein were applied by cup loading and
focused using the IPGphor 3 electrophoresis unit (GE Healthcare,
Waukesha, WI, USA). For the second dimension, IPG strips were
reduced for 15 min in SDS-equilibration buffer (6 M urea,
50 mM Tris-HCl, pH 8.8, 20% glycerol, 10% SDS, 1% w/v
DTT, and a trace of bromophenol blue); proteins were then
alkylated in the same buffer containing 2.5% w/v iodoacetamide.
Second dimension separation was performed on 10% gel. The
same primary antibodies were used, with the exception of muscle
GP (Abcam, Cambrige, UK); a-tubulin (Sigma, Saint Louis, USA)
was used for data normalization.
Blue Native Gel Electrophoresis (BN-PAGE)
BN-PAGE [18] was performed with 3% to 12% polyacryl-
amide gradient gels. Proteins were extracted with 1% n-dodecyl-
b-D-maltoside and diluted with a buffer containing 1.5 M
aminocaproic acid, 2 mM EDTA, and 50 mM bis-Tris
(pH 7.0). Serva Blue G was added to solubilize proteins to a
final concentration of 0.01 mg/mg protein and 50 mg of protein
were loaded into each lane. Denatured proteins were resolved in
a second dimension and the following steps were the same as
those used in 2D analysis.
Statistical analysis
Differences in LDA gene expression were evaluated with a
permutation analysis and p-values were adjusted for multiple
comparisons using the False Discovery Rate control method [19].
The influence of other variables on gene expression was tested.
Each gene was adjusted to different linear models and all possible
variable combinations were tested. The model for qualitative
variables (sex, muscle biopsy, Martinuzzi index) was equivalent to
analysis of variance, and the model for numeric and quantitative
variables (age, amount of PYGM and LEP transcripts) was
equivalent to analysis of covariance. The statistical analysis for
immunoblotting was performed using SPSS (SPSS15.0, Chicago,
IL, USA). Differences between groups were analyzed with the
non-parametric Mann Whitney U test.
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Participant number Sex Age
a Muscle biopsy GP activity
b Genotype
c Clinical severity scale
d
P1 M 59 B 0 p.W798R/p.W798R 3
P2 M 18 NA 0 p.R194W/p.P797VfsX19 2
P3 M 34 NA 0 p.R50X/p.R94W 2
P4 M 19 NA 0 p.R50X/p.G205S 1
P5 M 22 B 0 p.R50X/p.G205S 2
P6 M 17 B 0 p.R50X/p.A660D 1
P7 M 13 B 0 p.R50X/p.W798R 3
P8 M 33 NA 0 p.R50X/p.W798R 0
P9 F 21 B 0 p.N134KfsX161/p.R491AfsX7 3
P10 M 18 Q 0 p.W388SfsX34/p.K754fsX49 2
P11 F 68 NA 0 p.R50X/p.L5vfsX22 0
P12 F 32 B 0 p.R50X/p.L5vfsX22 1
P13 F 63 NA 0 p.R50 X/p.Q73HfsX7 3
P14 F 40 B 0 p.R50X/p.534VfsX5 1
P15 M NA B 0 p.R50X/p.534VfsX5 1
P16 M 35 NA 0 p.R50X/p.K754NfsX49 2
P17 F 31 Q 0 p.R50X/p.R50X 2
P18 M 71 Q 0 p.R50X/p.R50X 0
P19 F 21 B 0 p.R50X/p.R50X 3
P20 M 52 NA 0 p.E125X/p.E125X 3
P21 F 56 Q 0 p.W798R/p.W798R 1
P22 F 20 Q 0 p.R50X/p.L354P 0
P23 F 51 Q 0 p.R50X/p.R50X 3
P24 M 51 B 0 p.R50X/PIM 3
P25 M 21 B 0 p.G205S/p.Q176_M177insVQ 2
P26 F 26 Q 10 PIM/PIM 2
P27 M 25 D 0 p. G174D/c.1827G.A2
P28 M NA NA 0 p.R50X/c.1969+214_2177+369del 2
P29 F 47 Q 0 p.R50X/p.R602W 3
P30 F 29 NA ND p.R50X/p.R50X 1
P31 M 51 NA ND p.R771PfsX33/p.R771PfsX33 1
P32 F 28 NA ND p.L5VfsX22/p.K754NfsX49 2
P33 M 61 Q 0 p.G205S/p.G205S 1
P34 M 23 NA ND p.R50X/p.A660D 1
P35 M 21 NA 0 p.R50X/p.R50X 3
C1 F 28 Q
C2 F 35 Q
C3 F 23 B
C4 M 27 B
C5 M 43 B
C6 F 50 B
C7 F 42 B
PIM, possible intronic mutation.
aAge at the time the skeletal muscle biopsy was collected.
bGP activity units are mmol/min/g tissue.
cMutations identified in the protein translation product are indicated by a ‘‘p’’ and in the transcript level by a ‘‘c’’ (www.hgvs.org/mutnomen). GenBank reference
sequences were NP_005600.1 and NM_005609.1.
dPatients’s clinical severity was classified based on a numerical scale following the criteria defined by Martinuzzi et al. [17]
Abbreviations: M, male; F, female; NA, data non available; B, biceps; Q, quadriceps; D, deltoid; ND, not determined;
doi:10.1371/journal.pone.0031718.t001
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Expression of ACACB, CAPN3, CADH15, CKMM, GYS1 and
SERCA1 is down-regulated in McArdle patients
Expression analyses were performed on skeletal muscle from 34
patients (P1–P34) and 5 healthy individuals (C1–C5) (17 women
and 22 men). Statistically significant differences between patients
and controls (p,0.01) were observed for 6 of the studies genes
studied (Figure 1A–1F): ACACB, CAPN3, CADH15, CKMM, GYS1
and SERCA1. Patients presented a lower amount of transcripts than
controls, for all of the 6 aforementioned genes. Additionally, 10
other genes showed significantly decreased expression in patients
compared with controls (p,0.05) (Supplementary Table S2).
The individuals included in the study group showed consider-
able heterogeneity for certain characteristics (Table 1). Therefore,
the data were reanalyzed to exclude these factors as the cause of
the differential gene expression, and no associations were
identified for sex, age, and muscle type. PYGM genotype was
analyzed by classifying the patients in three groups: (i) two
missense mutations, (ii) one missense mutation and one nonsense
mutation, or (iii) two nonsense mutations. The expression profile of
these genes was not influenced by the patients’ PYGM genotype.
On the other hand, to determine whether the amount of adipose
tissue in skeletal muscle could influence the gene expression
pattern, leptin (LEP) expression [20] was studied, and no
differences in content of LEP transcripts were found. This lack
of correlations, suggests that the differences in the expression
pattern was solely due to the existence of the enzyme (GP)
deficiency.
SERCA1 and muscle GS protein content were reduced in
patients
We studied the protein products from four of the genes
identified to be differentially expressed in patients. These included
SERCA1, GYS1, CAPN3 and CADH15. Immunoblots were
performed on 4 patients (P21, P30, P32 and P34) and 3 controls
(C2, C3, and C4). SERCA1 and glycogen synthase (GS) protein
levels were markedly decreased (showing a 75% and 50%
reduction respectively) in patients respect to controls (p,0.05)
(Figure 2). The upper GS band, corresponding to its expected
weight of 94 KDa, was even more markedly decreased, with a
72% reduction in patients. In addition, some lower GS bands
appeared, suggesting changes in the protein phosphorylation rate.
Patients presented reduced unphosphorylated muscle
GS and a near absence of unphosphorylated SERCA1
As in the immunoblot study, 2D gel analysis showed an absence
of muscle GP in patients (Figure 3). GS appeared as two clear spots
by 2D gel analysis (thin arrows), but the patients showed higher
amounts of acidic muscle GS (continuous thin arrow), which
corresponds to phosphorylated forms of muscle GS, whereas the
controls showed a higher amount of more basic muscle GS
(discontinuous thin arrow), corresponding to unphosphorylated
forms. Compared to the controls, patients showed a 20% reduction
in unphosphorylatedGS and a 60%increase inphosphorylated GS.
Similarly, SERCA1 protein presented as two differentiated spots,
but the spot corresponding to basic (unphosphorylated) SERCA1
was almost absent (thick arrow) in patients.
GP formed two protein complexes with GS, which were
lower in McArdle patients
BN-PAGE performed on a control sample (Figure 4A) showed 2
spots (continuous arrows) for muscle GP: a spot corresponding to a
complex running in a medium acrylamide concentration, and a
spot corresponding to a second complex, in a lower acrylamide
concentration, suggesting the presence of muscle GP in different
protein complexes. The composition of these complexes was
analysed by a second dimention electrophoresis (SDS-PAGE) and
subsequent immunoblotting. SERCA1 immunodetection revealed
no overlapping of the protein with muscle GP, suggesting no
interaction between both proteins. However, when the protein
complexes were analysed for the presence of muscle GS, two of the
three complexes previously detected for muscle GP in the first
dimension, overlapped with the signal for GS protein (discontin-
uous arrows), suggesting that both GS and GP are present in these
complexes. In patients P29 and P35, no signal was detected for
muscle GP in comparison with the control (C7) (data not shown).
When testing for muscle GS complexes in these patients, the same
complexes as those observed in controls were present, but the two
complexes normally containing muscle GP, showed a 70%
reduction (Figure 4B).
Discussion
This study evidences the potential of transcriptomic arrays
combined with proteomic analysis to identify proteins involved in
the pathophysiology of metabolic disorders affecting the skeletal
muscle. Given that sample size requirements for RNA studies are
much lower than those for protein analysis approaches, we first
performed tests on the expression profile of muscle transcripts with
the aim of identifying those genes whose expression was
significantly differential in patients. Amongst the 16 genes whose
transcripts levels were found to be significantly lower compared
with controls, we found both GYS1 and SERCA1 genes which we
decided to analyse at their protein level due to their well-known
key role in muscle function.
Skeletal muscle is the major site of insulin-stimulated glucose
uptake, and most of this glucose is stored as glycogen through GS
activity [21]. Evidence of deregulation in this pathway has been
reported in McArdle patients, who have decreased insulin action
in skeletal muscle compared with healthy controls after a
hyperinsulinemic clamp, resulting in lower glucose use and lower
GS activity [10]. McArdle patients have also been shown to have
low GS activity during exercise [12]. Immunoblotting results (see
Figure 2) are similar to those obtained in a previous study with
McArdle patients, both showing a decrease in GS protein
compared with healthy controls [10]. We also could identify
several bands that represent different phophorylated forms of the
enzyme. GS has 9 residues that can be phosphorylated, causing
progressive inactivation of the enzyme [21]. With the use of 2D
gels, we showed that, compared with controls, patients had an
increase of inactive GS and a decrease of active forms. Some
authors have shown that high glycogen in skeletal muscle causes
lower insulin-stimulated glycogen synthesis and decreased glyco-
gen synthase activation [22]. Therefore the high glycogen
accumulation in muscle biopsies of these patients could be one
of the contributors to GS inactivation.
BN-PAGE showed that GP forms two complexes in which GS is
also present. This is relevant as some alterations in GS activity and
phosphorylation occurring in McArdle patients cannot be fully
explained by the decrease of enzyme activities responsible for the
covalent modification of the enzyme [12]. The other two control
mechanisms involved are allosteric regulation and enzyme
translocation [11], but neither explains the low phosphorylation
rate of muscle GS in these patients. The presence of muscle GP-
GS complexes suggest that their common allosteric regulators and
covalent modifiers function better if both proteins are in physical
Transcriptomic Profile of McArdle Disease
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of Ca
2+ stores from the SR, which activates phosphorylase kinase;
this in turn, activates GP and inactivates GS, both by
phosphorylation. Protein complexes containing these two enzymes
are expected to allow more flexible, efficient, and faster coupling
between synthesis and degradation of glycogen [23]. The presence
Figure 1. Scatter-plots for the six genes presenting the highest differential expression between patients and controls (p,0.01). A.
Acetyl-CoA carboxylase beta (ACACB); B. Calpain III large subunit (CAPN3); C. M-cadherin (CADH15); D. Muscle creatine kinase (CKMM); E. Muscle
glycogen synthase (GYS1); F. Sarcoplasmic reticulum Ca
2+ ATPase 1 (SERCA1). Each subject is represented by a dot.
doi:10.1371/journal.pone.0031718.g001
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evidenced by the fact that McArdle patients presented 30% less
GS in comparison with healthy controls.
A decreased rate of Ca
2+ reuptake by the SR (through SERCA
pumps) can cause slowing of relaxation and contribute to
decreased muscle force production in fatigued muscles. Indeed,
muscle fatigue is usually accompanied by a slowing of relaxation
and high rates of glycolytic ATP production, since up to 80% of
the ATP consumed during contraction is required for optimum
muscle relaxation [24,25]. Thus, the decrease of SERCA1 protein
we found in our patients compared with controls is of particular
interest. Partial reductions in the activity [26] or total amount of
SERCA1 due to SERCA1 mutations cause a disorder known as
Brody myopathy [26], a rare skeletal muscle condition that shares
some common clinical features with McArdle disease, i.e.patients
experience progressive muscle stiffness during exercise, leading to
cramps [27]. Lack of SERCA1 also causes neonatal death in mice
[28] SERCA1 is a Ca
2+transporter ATPase located in the SR of
fast twitch, type II fibers. Thus, SERCA1 is essential for normal
development of contraction-relaxation cycles in these fibers, which
are mainly glycogenolytic and therefore more sensitive to GP
deficiency. Thus, SERCA1 reduction may preferentially affect
those exercise tasks involving type II muscle fibers, i.e. isometric
exercise, lifting weights or intense dynamic exercise (stair climbing,
running, walking at very brisk pace, bicycling). This hypothesis is
indirectly supported by the results of a recent study by our group
using electromyography, in which McArdle patients showed
excessive fiber recruitment during dynamic (cycle-ergometry)
exercise, a phenomenon which was more marked at high
intensities [29]. Interestingly, the low SERCA1 levels found in
2D gels in our McArdle patients is similar to that reported for
Brody patients [30], yet McArdle patients showed a preferential
reduction in SERCA1 unphosphorylated forms. Cuenda et al [30]
found that GP inactive status affects SERCA, producing a shift
towards its ATP binding conformation. Additionally, concentra-
tions of calcium, ATP, ADP, and Pi, as well as pH values [31] can
modify the phosphorylation rate in SERCA1, and some of these
factors are reported to be deregulated in McArdle disease, notably
increased [ADP] and [Pi] [4].
The biochemical bases of muscle fatigue in McArdle disease are
not fully understood and a reduction in sodium-phosphate
ATPases has been described as a possible cause of fatigability in
McArdle disease [32]. As mentioned above, SERCA1 downreg-
ulation may also participate in the early fatigue that McArdle
patients experience during exercise [3]. The reduction in both
ATPases could also be related, since a preferential glycogenolytic
energy supply and close membrane localization has been proposed
to exist between the glycolytic enzymes and these channels [33].
Although SERCA1 is not present in muscle GP complexes, some
Figure 2. Immunoblotting of patients and controls for SERCA1,
muscle GP, muscle GS, and cyclophilin A proteins. Upper panel:
immunobloting for the indicated proteins; Lower panel: densitometric
analysis for SERCA1 and muscle GS immunodetection. Intensity ratios of
protein bands to cyclophilin A are shown as mean6SD. Symbol:
* p,0.05; Upper, upper band of muscle GS immunoblotting; Lower,
lower band of muscle GS immunoblotting; Patients P21, P30, P32 and
P34; Controls C2, C3, C4. P: Patients; C: Controls.
doi:10.1371/journal.pone.0031718.g002
Figure 3. 2D gel analysis of muscle GP, muscle GS, SERCA,1 and a-tubulin in 2 controls and 2 patients. In the first dimension, isoelectric
focusing separated proteins by pH 3–11. In the second dimension, proteins were separated by molecular weight. Abbreviations: pI, isoelectric point;
MW, molecular weight. Patients P21, P35; Controls C6, C7. Thin arrow indicates acidic muscle GS, discontinuous arrow indicates basic muscle GS and
thick arrow indicates basic SERCA1.
doi:10.1371/journal.pone.0031718.g003
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Meyer and coworkers [34] isolated protein-glycogen complexes
and found glycogen particles and enzymes related with glycogen
metabolism, among them GP, in the light fraction, and elements of
the SR characterized by strong ATPase activity in the heavy
fraction. Other authors reported the presence of SR in the
sarcomeric I band, where glycogen deposits are located, and where
glycogen is markedly reduced during muscle activity [35].
Moreover, calcium uptake in the SR can be supported solely
through enzymatic breakdown of glycogen by GP [35,36].
The main findings of our study are schematized in Figure 5. In
summary, our results suggest that the absence of GP in McArdle
patients may result in down-regulation of two control points in the
metabolism of skeletal muscles, i.e. (i) SERCA1 protein levels and
phosphorylation and (ii) the amount of GS. SERCA1 downreg-
ulation in patients could result in impaired calcium transport in
type II muscle fibers, leading to early fatigability. On the other
hand, the muscle of McArdle patients shows a shift towards
inactive GS forms, protecting these patients from the occurrence
of muscle glycogen overload. Some contributors to GS inactivation
Figure 4. BN-PAGE of muscle GP, muscle GS, and SERCA1. A. BN-PAGE for control C4. In the first dimension (1D), acrylamide percentage
ranges from 3% to 12%. In the second dimension (2D), continuous arrows indicate the 2 protein complexes in which muscle GP participates.
Discontinuous arrows show muscle GS forming complexes with muscle GP. B. Second dimension of muscle GP BN-PAGE in a control (C7) and patients
(P29 and P35).
doi:10.1371/journal.pone.0031718.g004
Figure 5. Schematic representation of the main findings and conclusions (in grey squares) of our study with regard to the
pathophysiology of McArdle disease. Abbreviations: GS (glycogen synthase), GP [glycogen phosphorylase, muscle isoform (myopho-
sphorylase)], SERCA1 (sarcoplasmic reticulum Ca
2+-ATPase 1).
doi:10.1371/journal.pone.0031718.g005
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glycogen accumulation in skeletal muscle. Overall, this study
shows the existence of a link between muscle GP, muscle
contraction-relaxation, and glycogen synthesis that may have a
primary role in the pathophysiological events occurring in this
disorder.
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Table S1 Genes studied in the customized low density array.
The genes of study are classified in groups depending on their role
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